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Abstract
Purpose Data from two noninferiority trials of a
dexamethasone-sparing regimen were assessed for the impact
of acute nausea and vomiting on delayed outcome in patients
undergoing moderately emetogenic chemotherapy (MEC) or
anthracycline plus cyclophosphamide (AC).
Methods Chemo-naive patients were randomized to receive
palonosetron (0.25 mg IV) plus dexamethasone (8 mg IV)
on day 1 of chemotherapy, or the same regimen followed by
oral dexamethasone on days 2 and 3 in the MEC (n=237) and
AC (n=380) cohorts. Patients were divided into two groups
according to whether or not they experienced vomiting and/or
moderate-to-severe nausea during the acute phase (high- and
low-risk groups, respectively). Primary efficacy endpoint was
the complete protection (CP) against delayed vomiting and
moderate-to-severe nausea. Patient’s satisfaction (0–100 mm
visual analog scale) was also analyzed.
Results Among the 209 low-risk patients undergoing MEC,
delayed CP occurred in 82.9 % of those who received single-
dose dexamethasone and 89.8 % of those who received 3-day
dexamethasone (P=0.165). Of the 271 low-risk patients un-
dergoing AC, CPwas achieved in 71.7% of those treated with
single-dose dexamethasone and 84.2 % treated with 3-day
dexamethasone (P=0.019). In spite of these observations,
the patient satisfaction data was not influenced by dexameth-
asone regimen. In both cohorts, occurrence of acute vomiting
or moderate-to-severe nausea was the key independent-
predictor for delayed vomiting or nausea, respectively.
Conclusions The dexamethasone-sparing regimen provides
adequate delayed protection in patients undergoing MEC
who are at low risk for delayed symptoms, and can still be
discussed for low-risk AC patients as the daily difference in
control is modest. Additional dexamethasone doses can be
customized on the basis of occurrence or absence of acute
symptoms in the first cycle of MEC and even AC.
Keywords Palonosetron . Dexamethasone . Delayed CINV .
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Introduction
Optimal prevention for chemotherapy-induced nausea and
vomiting (CINV) depends on recognition of the intrinsic
emetogenicity of a chemotherapeutic agent as well as an under-
standing of its potential to induce acute symptoms (within the
first 24 h) or delayed symptoms (typically between days 2 and 5
after single-day chemotherapy) [1]. Delayed CINV may occur
in patients receiving moderately emetogenic chemotherapy
(MEC) containing cyclophosphamide, anthracyclines,
carboplatin, oxaliplatin, or irinotecan [1]. In addition, combina-
tion chemotherapy regimens often increase the potential to in-
duce CINV compared to most individual agents. Accordingly,
women who receive the combination of an anthracycline and
cyclophosphamide (AC) are at a particularly high risk of acute
and delayed CINV [2, 3]. In light of this, some of the major
anti-emetic guidelines have reclassified this combination as
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highly emetogenic [3, 4], while those of the MASCC organi-
zation have categorized MEC as AC or non-AC MEC [2].
Two recent phase III trials comparing a 1-day dexametha-
sone regimen to a 3-day dexamethasone regimen, both com-
bined with palonosetron on day 1, in patients undergoing ei-
ther a broad range of MEC regimens or AC showed similar
outcomes with the two regimens in both settings [5, 6]. In
addition, a meta-analysis of individual patient data from these
two studies provided evidence that, irrespective of age, the 1-
day regimen is not associated with a loss in overall anti-emetic
protection in women undergoing AC [7]. In spite of routine
use of prophylactic dexamethasone in oncology practice [8],
concerns remain about tolerability of this agent, especially
when administered as part of multi-day anti-emetic regimens
[9]. It is well known that the occurrence of delayed nausea and
vomiting may be strongly influenced by the control of these
symptoms within the first 24 h after chemotherapy initiation
[10, 11]. This evidence prompted us to reanalyze data from the
cohorts of patients undergoing either MEC or AC who were
included in the two clinical trials of the dexamethasone-
sparing regimen to provide separate estimates of effectiveness
against delayed CINV depending on whether or not vomiting
and significant (i.e., moderate-to-severe) nausea were con-
trolled in the acute phase. In the current analysis, efficacy
findings from the high-risk cohort of AC can provide a frame-
work for interpretation of the results from the cohort of MEC.
Overall, the estimates may permit to evaluate anti-emetic ef-
fectiveness in the delayed phase without the confounding ef-
fect due to the occurrence of acute symptoms. They also
should help clinicians in customized decision making about
whether or not to administer additional dexamethasone doses
in prevention of delayed CINV.
Patients and methods
Patients and treatment
The present reanalysis is based on two cohorts of chemo-naive
patients who were included in two randomized clinical studies
investigating the dexamethasone-sparing regimen [5, 6].
Patients who received either MEC for a solid tumor or AC-
containing chemotherapy for breast cancer, took the study
medication, and completed the follow-up period (days 1–5
following chemotherapy initiation) were evaluable according
to a modified intention-to-treat analysis.
Assessments
Patients made daily entries in their diary for 5 days after
starting chemotherapy. Patients included in the analysis
assessed the severity of nausea by either a visual analog scale
(VAS) [6] or a verbal category scale (no nausea, mild=did not
interfere with normal daily life; moderate=interfered with nor-
mal daily life; or severe=required the patient to be bedridden)
[5]. For the purpose of this post hoc analysis, patients were
divided into two groups according to the effectiveness of pro-
phylaxis against nausea and vomiting during the first 24 h
(acute phase): a low-risk group, which included patients who
experienced neither vomiting nor moderate-to-severe nausea
within the acute phase, and a high-risk group, which included
patients who experienced one or both of these symptoms. The
primary efficacy end point was the proportion of patients with
protection against both vomiting and moderate-to-severe nau-
sea on days 2 through 5 (delayed phase) after the first cycle of
chemotherapy. The secondary end points were protection
against delayed vomiting, protection against delayed
moderate-to-severe nausea, duration of delayed symptoms,
and maximum severity of delayed nausea. Duration was de-
fined according to the number of days during the delayed
phase (4-day period) when patients experienced either
vomiting or nausea: ≥2 out of the 4 days was considered
severe, and 1 out of the 4 days was considered less severe.
The patient’s satisfaction with anti-emetic coverage was
assessed by a satisfactionVAS that was a 100-mm linemarked
“not at all satisfied” at the left-hand end and “totally satisfied”
at the right-hand end. Patients completed the satisfaction VAS
on day 6 during their first cycle of chemotherapy.
Statistical analysis
For patients who rated the severity of their nausea on a VAS,
the daily scores were converted into verbal categories accord-
ing to the following schema: no nausea defined as a VAS score
of less than 5 mm; mild nausea defined as a VAS score of 5 to
24 mm; moderate nausea defined as a VAS score of 25 to
74 mm; and severe nausea defined as a VAS score of 75 to
100 mm. The cutoff selected for severe nausea was defined
according to the results of a prospective study evaluating the
concordance between a four-point verbal category scale and a
VAS in assessing nausea severity in patients undergoing che-
motherapy [12]. Fisher’s exact test was used to compare cat-
egorical variables in the low-risk and high-risk groups.
Multivariable logistic-regression models with occurrence
(yes vs. no) of either delayed vomiting or nausea (moderate-
to-severe or mild) as the dependent variable were generated to
test for differences between anti-emetic regimens, while con-
trolling for standard covariates (i.e., age, gender, and alcohol
consumption as appropriate) and the occurrence of acute
vomiting and moderate-to-severe nausea. To determine the
occurrence of first-order interactions between anti-emetic reg-
imen and standard covariates, they were included one by one
into the statistical model. If the interaction term was not sta-
tistically significant, it was removed from the model. Results
were reported as odds ratios (ORs) with associated 95 % con-
fidence intervals (CIs) and two-tailed P values. All the
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secondary analyses were evaluated in an explorative or de-
scriptive manner, and therefore, no adjustment for multiplicity
was applied. The reported P values are intended for interpre-
tation of trends, rather than for claims of significance. All P
values were two-tailed, and a P<0.05 was considered statisti-
cally significant. All statistical analyses were performed using
SAS software (version 9.1; SAS Institute, Cary, NC).
Results
Of the 624 evaluable patients who were enrolled in the two
clinical trials, 237 received a MEC regimen for a solid tumor
and 380 received AC for breast cancer. Seven patients under-
going AC for malignancy other than breast cancer (four in the
1-day regimen, and three in the 3-day regimen) were excluded
from the analysis. Table 1 lists the characteristics of the patients.
Protection against delayed vomiting and nausea
Among the low-risk patients undergoing MEC, there were no
statistically significant between-treatment differences accord-
ing to each of the three measures of protection: no occurrence
of both vomiting andmoderate-to-severe nausea during days 2
through 5 (primary end point 82.9 vs. 89.8 %, respectively, in
the 1- and 3-day regimens; risk difference [RD]=−6.9 %;
95 % CI, −16.3 to 2.5 %; P=0.165); no occurrence of
vomiting alone (89.2 vs. 93.9 %; RD=−4.7 %; 95 % CI,
−12.3 to 2.9 %; P=0.324); and no occurrence of moderate-
to-severe nausea alone (94.6 vs. 92.9 %; RD=3.3 %; 95% CI,
−4.8 to 8.3 %; P=0.776). Among the 28 patients at high-risk,
there were also no statistically significant differences between
the two treatments according to any of the three measures of
delayed protection (data not shown).
Among the low-risk women undergoing AC, the 1-day reg-
imen was significantly less effective than the 3-day regimen
according to two of the three measures of protection: no occur-
rence of both symptoms during days 2 through 5 (primary end
point 71.7 vs. 84.2 %, respectively; RD=−12.5 %; 95 % CI,
−22.4 to −2.6 %; P=0.019); no occurrence of vomiting alone
(87.7 vs. 94 %; RD=−6.3 %; 95 % CI, −13.2 to 0.6 %; P=
0.093); and no occurrence of moderate-to-severe nausea alone
(77.5 vs. 88.7 %; RD=−11.2 %; 95%CI, −20.1 to −2.2%; P=
0.016). Among the high-risk patients, the 1-day regimen result-
ed in much less control of delayed symptoms than the 3-day
regimen but the differences were statistically significant for
only two of the three measures of protection: no occurrence
of both symptoms during days 2 through 5 (14.6 vs. 42.6 %,
respectively; RD=−28 %; 95 % CI, −45.4 to −10.7 %; P=
0.002); no occurrence of delayed vomiting alone (54.2 vs.
67.2 %; RD=−13.1 %; 95 % CI, −31.4 to 5.4 %; P=0.173);
and no occurrence of moderate-to-severe nausea alone (25 vs.
49.2 %; RD=−24.2 %; 95 % CI, −42.6 to −5.8 %; P=0.011).
Daily protection against delayed symptoms
Among the low-risk patients undergoingMEC, no statistically
significant incremental improvement (i.e., the between-
treatment difference) was observed with additional dexameth-
asone doses for control of either vomiting or moderate-to-
severe nausea during each day of the delayed phase (Fig. 1).
Among the patients at high risk, there were no significant
between-treatment differences for control of delayed vomiting
or moderate-to-severe nausea at each time point.
Among the low-risk patients undergoing AC, the incre-
mental improvement observedwith additional dexamethasone
doses for vomiting control was of only minimal magnitude
(≤5 percentage points) during each day of the delayed phase
(Fig. 1). The incremental improvement for control of
moderate-to-severe nausea was significant but of modest mag-
nitude on day 2 (9 percentage points; P=0.018) and on day 3
(8 percentage points; P=0.035) post-chemotherapy. As ex-
pected, the incremental improvement observed with addition-
al dexamethasone doses was of greater magnitude among pa-
tients in the high-risk group (Fig. 1). There were no significant
between-treatment differences in the proportion of patients
protected against delayed vomiting on days 2 through 5
post-chemotherapy. Additional dexamethasone doses im-
proved to a remarkable extent the protection rates against
moderate-to-severe nausea on day 2 (P=0.083), on day 3
(P=0.003), and on day 4 (P=0.024) post-chemotherapy.
Duration and severity of delayed symptoms
Irrespective of anti-emetic subgroup, there were no significant
differences in duration of either delayed vomiting or delayed
nausea in patients undergoing MEC who were at high or low
risk (Table 2). Severe nausea was seldom observed in the low-
risk group: one of 38 patients in the 1-day dexamethasone
subgroup (2.6 %) and one of 30 in the 3-day dexamethasone
subgroup (3.3 %) recorded severe nausea on at least 1 day in
the delayed phase. Likewise, the patients at high risk seldom
reported severe nausea: one of nine patients in the 1-day dexa-
methasone subgroup and none of ten in the 3-day dexameth-
asone subgroup recorded severe nausea on at least 1 day in the
delayed phase.
Irrespective of anti-emetic subgroup, there were no sig-
nificant differences in duration of either delayed vomiting
or delayed nausea in patients undergoing AC who were at
high or low risk (Table 3). Among the nauseated women at
low risk, the severity of delayed nausea significantly dif-
fered between the two treatments (P=0.039). Severe nausea
was seldom observed in the low-risk group: 6 of 70 pa-
tients in the 1-day dexamethasone subgroup (8.6 %) and 2
of 55 in the 3-day dexamethasone subgroup (3.6 %) record-
ed severe nausea on at least 1 day in the delayed phase.
The high-risk patients were more likely to report severe
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nausea: 16 of 45 patients in the 1-day dexamethasone sub-
group (35.6 %) and 10 of 48 in the 3-day dexamethasone
subgroup (20.8 %) recorded severe nausea on at least 1 day
in the delayed phase.
Prediction of delayed CINV
In the MEC cohort, the first-order interactions of delayed
vomiting or nausea between anti-emetic regimen and each
Table 1 Baseline characteristics
of the patients by chemotherapy
cohort
Characteristic by
cohort
Palo plus 1-day Dex Palo plus 3-day Dex P valuea
N % N %
MEC, evaluable patients 125 100 112 100
Age (years)
Median (min–max) 59 (31–77) 60 (35–80)
<50 years 27 21.6 24 21.4 1.0
Gender 0.515
Male 63 50.4 51 45.5
Female 62 49.6 61 54.5
Early stage disease 61 48.8 65 58.0 0.192
Primary tumor 0.792
Breast 28 22.4 31 27.7
Colorectal 66 52.8 53 47.3
Lung 15 12.0 13 11.6
Other 16 12.8 15 13.4
Chemotherapy regimen 0.840
Oxaliplatin-based 63 50.4 52 46.4
Carboplatin-based 20 16.0 16 14.3
Irinotecan-based 14 11.2 15 13.4
Otherb 28 22.4 29 25.9
Alcohol consumption 0.604
Never 67 53.6 56 50.0
Everyday 58 46.4 56 50.0
Risk group 0.841
Lowc 111 88.8 98 87.5
Highd 14 11.2 14 12.5
AC, evaluable patients 186 100 194 100
Age (years)
Median (min–max) 51 (28–77) 50 (26–78)
<50 years 81 43.5 93 47.9 0.411
Early-stage breast cancer 186 100 194 100
Alcohol consumption 0.559
Never/Occasionallye 174 93.5 178 91.7
Everyday 12 6.5 16 8.3
Risk group 0.257
Lowc 138 74.2 133 68.6
Highd 48 25.8 61 31.4
Palo palonosetron, Dex dexamethasone, MEC moderately emetogenic chemotherapy, AC anthracycline (doxo-
rubicin or epirubicin) plus cyclophosphamide
a Fisher’s exact test or chi-square test (two-tailed)
b Patients undergoing anthracycline or cyclophosphamide-containing chemotherapy
c Low-risk patients were free from both vomiting and moderate-to-severe nausea in the acute phase
dHigh-risk patients experienced vomiting or moderate-to-severe nausea in the acute phase
e Including 53 patients with missing data for alcohol consumption
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standard covariate were not statistically significant. In the ad-
justed models, only acute vomiting was an independent pre-
dictor for delayed vomiting (P=0.045), while only acute
moderate-to-severe nausea independently predicted for de-
layed nausea (P=0.0007; Table 4).
In the AC cohort, the first-order interaction of de-
layed vomiting between anti-emetic regimen and age
was statistically significant (P=0.020). In the model in-
cluding the interaction term, the 1-day dexamethasone
regimen, acute vomiting, and acute moderate-to-severe
nausea were all associated with a significantly higher
odds of developing delayed vomiting (P=0.005, P=
0.001, and P=0.0009 for the three comparisons, respec-
tively; Table 5). However, vomiting or moderate-to-
severe nausea occurring in the acute phase were strong
predictors for delayed vomiting. Only acute moderate-
to-severe nausea was an independent predictor for de-
layed nausea (P<0.0001; Table 5).
Fig. 1 Proportions of patients in the MEC and AC cohorts who
experience no vomiting or moderate-to-severe nausea in the delayed
phase, by risk and treatment groups. Low-risk patients were free from
vomiting andmoderate-to-severe nausea during the acute phase; high-risk
patients experienced vomiting or moderate-to-severe nausea during the
acute phase. Patients received palonosetron plus dexamethasone on day 1
either with or without dexamethasone on days 2 and 3.MEC moderately
emetogenic chemotherapy, AC anthracycline plus cyclophosphamide,
Dex dexamethasone
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Patient’s satisfaction with anti-emetic regimen
A total of 227 VAS satisfaction ratings were available for
analysis in the MEC cohort. Mean satisfaction with anti-
emetic therapy for the 118 patients in the 1-day regimen sub-
group did not differ from that for the 109 patients in the 3-day
regimen subgroup (8.62; 95 % CI, 8.27 to 8.96; and 8.42;
95 % CI, 8.02 to 8.82, respectively; P=0.892; Mann-
Whitney U test). There was no significant between-treatment
difference in the mean VAS scoring in the low-risk group (1-
day regimen: mean 8.67; 95 % CI, 8.31 to 9.03; 3-day regi-
men: mean 8.72; 95 % CI, 8.37 to 9.08; P=0.540). There was
also no significant between-treatment difference in the mean
VAS scoring in the high-risk group (1-day regimen: mean
8.18; 95 % CI, 6.80 to 9.57; 3-day regimen: mean 6.36;
95 % CI, 4.53 to 8.18; P=0.089). However, irrespective of
anti-emetic subgroup, the mean VAS scoring for treatment
satisfaction was significantly different between the low-risk
and high-risk groups (mean difference, 1.46; 95 % CI, 0.67
to 2.25; P=0.003).
A total of 375 VAS satisfaction ratings were available for
analysis in the AC cohort. Mean satisfaction with anti-emetic
therapy for the 185 patients in the 1-day regimen subgroup did
not differ from that for the 190 patients in the 3-day regimen
subgroup (6.98; 95 % CI, 6.47 to 7.49, and 7.39; 95 % CI,
6.92 to 7.85, respectively; P=0.330). There was no significant
between-treatment difference in the mean VAS scoring in the
low-risk group (1-day regimen: mean 7.82; 95 % CI, 7.31 to
8.33; 3-day regimen: mean 8.24; 95 % CI, 7.77 to 8.71; P=
0.345). There was also no significant between-treatment dif-
ference in the mean VAS scoring in the high-risk group (1-day
regimen: mean 4.57; 95 % CI, 3.48 to 5.66; 3-day regimen:
mean 5.54; 95 % CI, 4.61 to 6.47; P=0.205). However, irre-
spective of anti-emetic subgroup, the mean VAS scoring for
treatment satisfaction was significantly different between the
low-risk and high-risk groups (mean difference, 2.91; 95 %
CI, 2.21 to 3.62; P<0.0001).
Discussion
There may be a specific interest inminimizing the total dose of
dexamethasone for the prevention of CINV in all patients, and
specifically those who experience dexamethasone-related side
effects or in patients with pre-existing conditions like diabetes
that could be exacerbated by corticosteroid use [13]. However,
any clinical benefit conferred by reducing the overall exposure
to dexamethasone should not compromise the ability to
Table 2 Duration and severity of
delayed CINV in patients
undergoing MEC by risk group
End point Risk groupa Palo plus 1-day Dex,
n/N (%)
Palo plus 3-day Dex,
n/N (%)
P valueb
Duration of delayed vomitingc High 1.0
1 day 3/5 (60) 1/2 (50)
≥2 days 2/5 (40) 1/2 (50)
Duration of delayed nauseac High 0.303
1 day 3/9 (33.3) 1/10 (10)
≥2 days 6/9 (66.7) 9/10 (90)
Severity of delayed nausea High 1.0
Mild 5/9 (55.6) 6/10 (60)
Moderate-to-severe 4/9 (44.4) 4/10 (40)
Duration of delayed vomitingc Low 0.615
1 day 8/12 (66.7) 5/6 (83.3)
≥2 days 4/12 (33.3) 1/6 (16.7)
Duration of delayed nauseac Low 0.328
1 day 15/38 (39.5) 16/30 (53.3)
≥2 days 23/38 (60.5) 14/30 (46.7)
Severity of delayed nausea Low 0.539
Mild 32/38 (84.2) 23/30 (76.7)
Moderate-to-severe 6/38 (15.8) 7/30 (23.3)
MECmoderately emetogenic chemotherapy, Palo palonosetron, Dex dexamethasone, N total number of patients
experiencing symptom
aHigh-risk patients experienced vomiting or moderate-to-severe nausea during the acute phase; low-risk patients
were free from vomiting and moderate-to-severe nausea during the acute phase
b Fisher’s exact test (two-tailed)
c Assessment over 4-day period
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effectively control CINV. Hence, we investigated the impact
of vomiting or significant nausea occurring in the first 24 h
after chemotherapy initiation, the most important risk factor
for delayed CINV, on delayed outcome of palonosetron plus
Table 3 Duration and severity of
delayed CINV in women
undergoing AC by risk group
End point Risk groupa Palo plus 1-day Dex,
n/N (%)
Palo plus 3-day Dex,
n/N (%)
P valueb
Duration of delayed vomitingc High 1.0
1 day 14/22 (63.6) 12/20 (60)
≥2 days 8/22 (36.4) 8/20 (40)
Duration of delayed nauseac High 0.798
1 day 10/45 (22.2) 9/48 (18.8)
≥2 days 35/45 (77.8) 39/48 (81.2)
Severity of delayed nausea High 0.111
Mild 9/45 (20) 17/48 (35.4)
Moderate-to-severe 36/45 (80) 31/48 (64.6)
Duration of delayed vomitingc Low 1.0
1 day 11/17 (64.7) 6/8 (75)
≥2 days 6/17 (35.3) 2/8 (25)
Duration of delayed nauseac Low 0.058
1 day 28/70 (40) 13/55 (23.6)
≥2 days 42/70 (60) 42/55 (76.4)
Severity of delayed nausea Low 0.039
Mild 39/70 (55.7) 41/55 (74.5)
Moderate-to-severe 31/70 (44.3) 14/55 (25.5)
AC anthracycline plus cyclophosphamide, Palo palonosetron, Dex dexamethasone, N total number of patients
experiencing symptom
aHigh-risk patients experienced vomiting or moderate-to-severe nausea during the acute phase; low-risk patients
were free from vomiting and moderate-to-severe nausea during the acute phase
b Fisher’s exact test (two-tailed)
c Assessment over 4-day period
Table 4 Results of multivariable
logistic-regression analysis of
delayed vomiting and nausea
among 237 patients undergoing
MEC
Variable Odds ratioa (95 % CI) P value
Delayed vomiting
Anti-emetic prophylaxis (1-day vs. 3-day regimen)b 1.89 (0.76–4.71) 0.172
Age (<50 vs. ≥50 years) 0.62 (0.18–2.14) 0.452
Gender (female vs. male) 0.69 (0.27–1.77) 0.435
Alcohol consumption (never vs. regularly) 1.27 (0.49–3.27) 0.626
Acute vomiting (yes vs. no) 5.40 (1.04–28.1) 0.045
Acute moderate-to-severe nausea (yes vs. no) 2.04 (0.56–7.39) 0.277
Delayed nausea (moderate-to-severe or mild)
Anti-emetic prophylaxis (1-day vs. 3-day regimen)b 1.19 (0.68–2.07) 0.546
Age (<50 vs. ≥50 years) 1.12 (0.55–2.25) 0.756
Gender (female vs. male) 1.46 (0.81–2.64) 0.204
Alcohol consumption (never vs. regularly) 0.93 (0.52–1.67) 0.804
Acute vomiting (yes vs. no) 0.76 (0.17–3.45) 0.727
Acute moderate-to-severe nausea (yes vs. no) 5.98 (2.11–16.9) 0.0007
MEC moderately emetogenic chemotherapy, CI confidence interval
a An odds ratio larger than 1 indicates an increased likelihood of experiencing delayed vomiting or nausea
b Patients received palonosetron plus dexamethasone on day 1 either with or without dexamethasone on days 2
and 3
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single-dose dexamethasone in patients included in two ran-
domized trials [5, 6]. The post hoc analysis described here
yielded several key findings in patients at either low- or
high-risk for delayed symptoms who received the same pro-
phylaxis for acute CINV:
1. The vast majority of low-risk patients undergoing com-
monly used MEC regimens achieve delayed protection
against vomiting and moderate-to-severe nausea, regard-
less of dexamethasone regimen.
2. In the AC cohort, the dexamethasone-sparing regimen is
significantly less effective in delayed protection against
either symptom also in patients at low risk; however, the
1-day regimen is significantly less effective against sig-
nificant nausea alone but not vomiting alone in the de-
layed phase.
3. In the MEC cohort, the only independent predictor for
delayed CINV is the occurrence of acute symptoms, re-
gardless of anti-emetic regimen, age, gender, and alcohol
consumption.
4. In the AC cohort, a key predictor for delayed vomiting is
the occurrence of acute symptoms, while significant nau-
sea occurring in the acute phase is the only predictor for
delayed nausea.
5. Irrespective of chemotherapy cohort, the dexamethasone-
sparing regimen has no apparent impact on the overall
patient’s satisfaction with anti-emetic treatment in both
the low-risk and high-risk groups.
From a clinical point of view, the main findings of the
current analysis are that very few patients in the MEC
cohort experienced acute CINV and the dexamethasone-
sparing regimen achieved an excellent control of delayed
symptoms in patients with no acute CINV. In addition,
there were no between-treatment differences in the duration
of delayed symptoms as well as the severity of delayed
nausea occurring in patients at low risk. Since both dura-
tion and severity of delayed symptoms may impact on
health-related quality of life [14], the finding can be con-
sidered as further proof of the effectiveness of the
dexamethasone-sparing regimen in the setting of MEC.
More recently, a phase III, noninferiority trial involving
305 patients undergoing mainly oxaliplatin-, irinotecan-,
or carboplatin-based MEC (73, 13, and 12 % of the en-
rolled patients, respectively) also demonstrated that
palonosetron plus single-dose dexamethasone provide pro-
tection against CINV which was noninferior to that of the
same regimen with dexamethasone for 3 days [15].
We showed that, among low-risk AC patients, there is a
statistically significant improvement associated with addition-
al dexamethasone doses in protection against delayed
vomiting and significant nausea, and this benefit is due to an
improved control of moderate-to-severe nausea. However, cli-
nicians should also keep in mind that the between-treatment
difference in daily control of delayed moderate-to-severe nau-
sea is of onlymodest magnitude (less than 10% on each single
day) among low-risk patients. It is interesting to note that the
occurrence of significant nausea in the acute phase was the
only independent predictor for delayed nausea in the AC co-
hort, and there was no apparent impact on the overall patient’s
satisfaction with the 3-day dexamethasone regimen. Overall,
the results from the current analysis should encourage clini-
cians to discuss the dexamethasone-sparing regimen for low-
risk AC patients. To put the findings in a proper clinical
Table 5 Results of multivariable
logistic-regression analysis of
delayed vomiting and nausea
among 380 women undergoing
AC
Variable Odds ratioa (95 % CI) P value
Delayed vomiting
Anti-emetic prophylaxis (1-day vs. 3-day regimen)b 3.28 (1.43–7.52) 0.005
Age (<50 vs. ≥50 years) 1.23 (0.50–3.03) 0.653
Interaction (anti-emetic prophylaxis) (age) 0.32 (0.09–1.06) 0.062
Alcohol consumption (never vs. regularly) 0.42 (0.15–1.13) 0.085
Acute vomiting (yes vs. no) 3.48 (1.65–7.33) 0.001
Acute moderate-to-severe nausea (yes vs. no) 3.41 (1.66–7.00) 0.0009
Delayed nausea (moderate-to-severe or mild)
Anti-emetic prophylaxis (1-day vs. 3-day regimen)b 1.56 (1.00–2.43) 0.050
Age (<50 vs. ≥50 years) 1.29 (0.82–2.02) 0.271
Alcohol consumption (never vs. regularly) 0.76 (0.33–1.75) 0.521
Acute vomiting (yes vs. no) 1.07 (0.50–2.33) 0.853
Acute moderate-to-severe nausea (yes vs. no) 11.6 (4.94–27.2) <0.0001
AC anthracycline plus cyclophosphamide, CI confidence interval
a An odds ratio larger than 1 indicates an increased likelihood of experiencing delayed vomiting or nausea
b Patients received palonosetron plus dexamethasone on day 1 either with or without dexamethasone on days 2
and 3
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perspective, we must consider that current guidelines recom-
mend adding a neurokinin-1 (NK1) receptor antagonist (RA)
to the 5-HT3RA and dexamethasone regimen for the optimal
prevention of CINV caused by AC [2–4]. A recent phase III,
superiority trial comparing palonosetron, dexamethasone, and
aprepitant on day 1 followed by either aprepitant or dexameth-
asone on days 2 and 3 in this setting failed to detect any
dexamethasone-induced improvement in the rate of delayed
complete response (primary end point) as well as in any sec-
ondary end point including no nausea, no significant nausea,
maximum severity of nausea, and duration of nausea in the
delayed phase [16]. In addition, significantly more women
receiving dexamethasone on days 2 and 3 experienced insom-
nia or heartburn in the delayed period following the first cycle
of AC. Since most of the improvement produced by the three-
drug regimen is expected to occur in patients at low risk, these
findings support the view that the potential benefit of further
dexamethasone in these patients may be overcome when a
NK1RA is given on day 1. Consistent with this supposition,
in a recent trial of breast cancer patients receiving AC, 67 %
had delayed complete protection, 82 % had no delayed
vomiting and 77 % experienced no delayed moderate-to-
severe nausea among patients given the 1-day three-drug reg-
imen of NEPA (a combination of the novel NK1RA netupitant
and palonosetron) and dexamethasone, versus 60, 76, and
71%, respectively, of patients who received palonosetron plus
single-dose dexamethasone [17]. Given the consistency of
results and the total number of patients enrolled onto these
two trials with NK1RAs, we suggest that in breast cancer
patients at low risk treated with the 1-day three-drug regimen
the benefit of further dexamethasone may have little relevance
for the control of delayed CINV. Interestingly, it has been
reported that in breast cancer patients undergoing the first
cycle of AC nausea continued to affect more patients than
vomiting, even when they received aprepitant plus dexameth-
asone on days 2 and 3 post-chemotherapy [18]. If a NK1RA is
not available, the clinicians should consider that there are cur-
rently no data from adequately powered randomized trials that
evaluated the efficacy of a dexamethasone-sparing approach
with an older 5-HT3RA compared to the same approach with
palonosetron in the setting of AC. It also should be noted that
the dexamethasone-sparing approach has been developed tak-
ing advantage of the superiority of palonosetron, when admin-
istered alone or in combination with dexamethasone, com-
pared to a single dose of older antagonists in the control of
delayed CINV caused by non-AC and AC MEC [19–21].
One limitation of this study is that it is a post hoc analysis.
In spite of this, the overall results we gathered on the effec-
tiveness of the dexamethasone-sparing regimen in the homo-
geneous cohort of AC, which has a particularly high-risk for
CINVas a whole, support and extend the clinical relevance of
the findings observed in the MEC cohort at lower risk.
Another limitation is that pre-chemotherapy patient’s anxiety
and personal history of nausea or vomiting were not recorded,
and these data might help the decision-making process [22].
The current analysis strongly supports the position that
optimizing the overall risk-benefit ratio for dexamethasone is
possible because the choice of using additional steroid doses
can be customized on the basis of the occurrence or absence of
acute CINV in the first cycle of MEC, and possibly in AC.
Accordingly, additional dexamethasone doses could be of-
fered selectively to patients receiving the dexamethasone-
sparing regimen who experienced vomiting or significant nau-
sea in the acute or delayed phases following the first cycle of
MEC or AC.
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